Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13196027 | 0.94 | SIGMAR1 (0.38) | ALDH1A1KDM4EKDM1AGAAMEN1 | |
| SCHEMBL259387 | 0.86 | MAPK1 (0.40) | ALDH1A1KDM4EKDM1AGAAMEN1 | |
| SCHEMBL10924619 | 0.84 | ALDH1A1 (0.39) | ALDH1A1KDM4EMAPK1 | |
| SCHEMBL11575418 | 0.84 | — | — | |
| SCHEMBL12712715 | 0.79 | — | — | |
| SCHEMBL10930283 | 0.79 | HSD11B1 (0.42) | ALDH1A1KDM4EMAPK1 | |
| SCHEMBL1277016 | 0.79 | HRH3 (0.52) | ALDH1A1KDM4EMEN1KMT2APOLB | |
| SCHEMBL13174457 | 0.78 | MEN1 (0.36) | ALDH1A1KDM4EKDM1AGAAMEN1 | |
| SCHEMBL17526810 | 0.77 | MAPK1 (0.32) | KDM1AMAPK1 | |
| SCHEMBL17527004 | 0.77 | MAPK1 (0.32) | KDM1AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10881608-B2 | Biodegradable intravitreal tyrosine kinase implants | ALLERGAN, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20190038551-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | ALLERGAN, INC. | 2019-02-07 | — | — | US | disclosed |
| US-20170348320-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORP (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170348320-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORP (US) | 2017-12-07 | — | — | US | disclosed |
| US-9580395-B2 | Compositions of dual thyrointegrin antagonists and use in vascular-associated disorders | VASCULAR VISION PHARMACEUTICAL COMPANY (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580395-B2 | Compositions of dual thyrointegrin antagonists and use in vascular-associated disorders | VASCULAR VISION PHARMACEUTICAL COMPANY (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160199297-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | ALLERGAN, INC. | 2016-07-14 | — | — | US | disclosed |
| US-9233070-B2 | Biodegradable intravitreal tyrosine kinase implants | ALLERGAN, INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-9056045-B2 | Intraocular biodegradable microspheres | ALLERGAN, INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-20150126505-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORP (US) | 2015-05-07 | — | — | US | disclosed |
| US-20080254096-A1 | Using polyvinyl alcohol free biodegradable polymer matrix; reducing side effects, invasive procedures and high transient concentrations; glaucoma, proliferative vitreoretinopathy | ALLERGAN,INC (US) | 2008-10-16 | — | — | US | disclosed |
| US-7414054-B2 | 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7402583-B2 | Substituted quinolines as antitumor agents | ASTRZENCA AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-7402583-B2 | Substituted quinolines as antitumor agents | ASTRZENCA AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-20080125411-A1 | DISPIRO 1,2,4-TRIOXOLANE ANTIMALARIALS | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2008-05-29 | — | — | US | disclosed |
| US-20080125411-A1 | DISPIRO 1,2,4-TRIOXOLANE ANTIMALARIALS | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2008-05-29 | — | — | US | disclosed |
| US-20080096928-A9 | Indole compounds that modify translational control of Hepatitis C virus | PTC THERAPEUTICS, INC. | 2008-04-24 | — | — | US | disclosed |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | AMBIT BIOSCIENCES CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070021407-A1 | Substituted quinolines as antitumor agents | ASTRAZENECA | 2007-01-25 | — | — | US | disclosed |
| US-20070021407-A1 | Substituted quinolines as antitumor agents | ASTRAZENECA | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096928-A9 | Indole compounds that modify translational control of Hepatitis C virus | EIF2AK2, INMT, IDO1 | ALDH1A1 1556/4885KDM4E 433/4885KDM1A 975/4885 |
| US-20150126505-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | GRK2, GRK4, GRK3 | ALDH1A1 3704/4885KDM4E 4443/4885KDM1A 4491/4885 |
| US-20070021407-A1 | Substituted quinolines as antitumor agents | NR1H3, NR1H2, NR0B1 | ALDH1A1 3767/4885KDM4E 2903/4885KDM1A 2923/4885 |
| US-20080125411-A1 | DISPIRO 1,2,4-TRIOXOLANE ANTIMALARIALS | DHODH, THPO, SQLE | ALDH1A1 319/4885KDM4E 3438/4885KDM1A 3291/4885 |
| US-10881608-B2 | Biodegradable intravitreal tyrosine kinase implants | KDR, PTK2B, DSTYK | ALDH1A1 1500/4885KDM4E 860/4885KDM1A 749/4885 |
| US-20170348320-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | GRK2, GRK4, GRK3 | ALDH1A1 3704/4885KDM4E 4443/4885KDM1A 4491/4885 |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | GRK2, GRK3, BLK | ALDH1A1 3405/4885KDM4E 1585/4885KDM1A 2054/4885 |
| US-20160199297-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | KDR, PTK2B, DSTYK | ALDH1A1 1537/4885KDM4E 888/4885KDM1A 761/4885 |
| US-20190038551-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | KDR, PTK2B, DSTYK | ALDH1A1 1537/4885KDM4E 888/4885KDM1A 761/4885 |
| US-20080254096-A1 | Using polyvinyl alcohol free biodegradable polymer matrix; reducing side effects, invasive procedures and high transient concentrations; glaucoma, proliferative vitreoretinopathy | VEGFA, PTK2, KDR | ALDH1A1 1521/4885KDM4E 1382/4885KDM1A 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.